Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study

Dan Lewer1,2,3*, Brian Eastwood2, Martin White2, Thomas D. Brothers1,3,4, Martin McCusker5, Caroline Copeland6,7, Michael Farrell3, Irene Petersen8

1 Department of Epidemiology and Public Health, University College London, London, United Kingdom, 2 Alcohol, Drugs, Tobacco and Justice Division, Public Health England, London, United Kingdom, 3 National Drug and Alcohol Research Centre, University of New South Wales, Kensington, Australia, 4 Department of Medicine, Dalhousie University, Halifax, Canada, 5 Lambeth Service User Council, London, United Kingdom, 6 Institute of Pharmaceutical Sciences, King’s College London, London, United Kingdom, 7 National Programme on Substance Abuse Deaths, St George’s, University of London, London, United Kingdom, 8 Department of Primary Care and Population Health, University College London, London, United Kingdom

* d.lewer@ucl.ac.uk

Abstract

Background

Hospital patients who use illicit opioids such as heroin may use drugs during an admission or leave the hospital in order to use drugs. There have been reports of patients found dead from drug poisoning on the hospital premises or shortly after leaving the hospital. This study examines whether hospital admission and discharge are associated with increased risk of opioid-related death.

Methods and findings

We conducted a case-crossover study of opioid-related deaths in England. Our study included 13,609 deaths between January 1, 2010 and December 31, 2019 among individuals aged 18 to 64. For each death, we sampled 5 control days from the period 730 to 28 days before death. We used data from the national Hospital Episode Statistics database to determine the time proximity of deaths and control days to hospital admissions. We estimated the association between hospital admission and opioid-related death using conditional logistic regression, with a reference category of time neither admitted to the hospital nor within 14 days of discharge. A total of 236/13,609 deaths (1.7%) occurred following drug use while admitted to the hospital. The risk during hospital admissions was similar or lower than periods neither admitted to the hospital nor recently discharged, with odds ratios 1.03 (95% CI 0.87 to 1.21; p = 0.75) for the first 14 days of an admission and 0.41 (95% CI 0.30 to 0.56; p < 0.001) for days 15 onwards. 1,088/13,609 deaths (8.0%) occurred in the 14 days after discharge. The risk of opioid-related death increased in this period, with odds ratios of 4.39 (95% CI 3.75 to 5.14; p < 0.001) on days 1 to 2 after discharge and 2.09 (95% CI 1.92 to 2.28; p < 0.001) on days 3 to 14. 11,629/13,609 deaths (85.5%) did not occur close to a hospital admission, and the remaining 656/13,609 deaths (4.8%) occurred in hospital
following admission due to drug poisoning. Risk was greater for patients discharged from psychiatric admissions, those who left the hospital against medical advice, and those leaving the hospital after admissions of 7 days or more. The main limitation of the method is that it does not control for time-varying health or drug use within individuals; therefore, hospital admissions coinciding with high-risk periods may in part explain the results.

Conclusions
Discharge from the hospital is associated with an acute increase in the risk of opioid-related death, and 1 in 14 opioid-related deaths in England happens in the 2 weeks after the hospital discharge. This supports interventions that prevent early discharge and improve linkage with community drug treatment and harm reduction services.

Author summary

Why was this study done?

- The number of deaths due to poisoning by opioids such as heroin is increasing in England.
- The risk of dying due to a drug overdose varies across time, for example, deaths are common in the weeks after the release from prison or discharge from drug treatment.
- Hospital patients who use illicit drugs report undertreated pain and opioid withdrawal, and patients have overdosed in hospital toilets and car parks.
- Hospital admission and discharge may be an opportunity to help people who use illicit opioids.

What did the researchers do and find?

- We studied people who died due to a fatal drug overdose in England, where an opioid such as heroin contributed to the death.
- We looked at the history of hospital admissions for these individuals, and we assessed whether they were admitted to the hospital at the time of death or had recently been discharged.
- We found that fatal opioid overdoses are 4 times more likely in the 2 days after the hospital discharge than at other times, showing that hospital discharge is a high-risk time for people who use illicit opioids.
- We also found that some fatal opioid overdoses happened during hospital admissions, but the number was similar or lower than expected among people who use drugs in the community.
What do these findings mean?

- People who use illicit drugs such as heroin need extra support when being discharged from the hospital.
- Interventions that reduce the risk of fatal overdose, such as opioid agonist treatment and overdose response training with take-home naloxone (an antidote for opioid overdose), may be beneficial when provided in the hospital.
- Hospitals may need to improve training related to addictions and develop policies to implement these overdose reduction interventions.

Introduction

People who use illicit opioids such as heroin sometimes report unpleasant experiences when admitted to the hospital for medical treatment. In some cases, hospital staff are suspicious when patients describe their symptoms, believing they are “drug seeking” [1,2]. In other cases, staff are concerned about the safety of giving opioid-based medicines to patients who may be taking opioids from other sources. Sometimes, staff are too busy to verify a patient’s usual dose of methadone or buprenorphine or do not have sufficient knowledge or training about opioid dependence [3,4]. These factors can lead to inadequate pain control or delayed or insufficient opioid substitution [4]. Patients have also said that some staff are judgmental about illicit drug use and therefore hide the fact that they use drugs [5].

Opioid withdrawal can lead patients to leave the hospital to buy drugs. Some bring a supply into the hospital to keep them going, and some arrange for dealers to visit them while they are staying on a ward [3]. Surveys of hospital patients who use illicit opioids suggest that in-hospital use is common [5,6]. Using drugs in the hospital is associated with high-risk practices, including using alone in a toilet cubicle, rushing the procedure, taking a bigger dose to reduce the need for top-ups, and not having the usual equipment such as a new needle and syringe, a tourniquet, and sterile water [5].

There have been newspaper reports of hospital patients taking heroin and being found dead in a hospital toilet, car park, or another public place close to the hospital [7,8]. However, we do not know how many times this has happened or if hospital admissions increase the risk of opioid-related death. The period after discharge from the hospital may also be risky, because opioid tolerance may be reduced, and patients may be unwell and more susceptible to a drug overdose. This study examines whether the risk of opioid-related death is increased during hospital admission and in the period after discharge. We expected these periods to be associated with increased risk of opioid-related death.

Methods

Ethical approval

This study was approved by the Public Health England Research Ethics and Governance Group (PHE REGG), ref R&D412, on October 26, 2020. Data were anonymised before analysis, and personal identifiers such as name, address, or NHS number were not available to the research team.
This is a case-crossover study estimating the risk of opioid-related deaths associated with admission to the hospital. Case-crossover studies measure acute “triggering” effects of transient exposures [9]. They make within-subject comparisons in the exposure status when an event occurred (in this study, when someone died after using opioids) with the exposure status at other times. Case-crossover studies are one of a family of self-controlled study designs that only include participants who experienced an event. These designs focus on the timing of an event, in contrast to traditional epidemiological studies that focus on who experiences an event. This study is addressing the question “do hospital admission and discharge trigger opioid-related deaths?” We chose this design because it allows inclusion of a large proportion of cases and is statistically powerful, and it controls confounding more effectively than a cohort design that might compare people who use opioids and are admitted to the hospital with those not admitted.

Study participants
We studied opioid-related deaths among people in England aged 18 to 64 between January 1, 2010 and December 31, 2019 based on the date of death (rather than registration). We defined opioid-related deaths as those with an underlying cause of drug poisoning (using the UK Office for National Statistics definition of drug poisoning [10]: the International Classification of Diseases-10th Revision [ICD-10] codes X40-X44, X60-X64, X85, or Y10-14) and where an opioid is also specified (ICD-10 codes T40.0-T40.4 and T40.6) or if opioid dependence (ICD-10 F11) was the underlying cause of death. Coroners investigate drug-related deaths in England, including analysis of toxicology results. This means that the causes of death in this study have been validated to a greater degree than for most deaths. For simplicity, we refer to these deaths as “fatal opioid overdoses” in the title and author summary, although we use “opioid-related deaths” elsewhere to reflect the difficulty of attributing deaths to one specific drug.

Data were drawn from a database that includes mortality data from the UK Office for National Statistics and hospital records from the national Hospital Episode Statistics database, with probabilistic linkage between the 2 sources using the National Health Service (NHS) number, date of birth, sex, and home address [11]. This database does not include deaths if no linkage is found (most likely because the decedent was never admitted to the hospital). Using published mortality data [12], we estimated that 11.8% of deaths were excluded (Fig 1).

Control days
For each case, we sampled 5 days at random from the period 730 to 28 days prior to death, limiting to the same day of the week as death (Fig 2). The reason for limiting to the same day of the week is that both drug-related deaths and hospital admissions vary by weekday, which may cause confounding. Fewer hospital admissions and discharges occur at the weekend [13], while deaths due to drug poisoning peak on Saturday [14]. We chose the period 730 to 28 days prior to death to avoid control days that are too close to death and may have correlated exposures, while also allowing reasonable exchangeability in the probability of hospital admission. We then observed the exposure status on the control days. In sensitivity analysis, we repeated the study with control days sampled from the periods 365 to 28 days before death and 1,095 to 28 days before death.

Exposure status
Control days were classified as (A) currently admitted to the hospital (days 1 to 14 after admission); (B) currently admitted to hospital (15+ days after admission); (C) days 1 or 2 after
discharge; (D) days 3 to 14 after discharge; and (E) neither hospitalised nor recently discharged (i.e., time spent in the community).

To understand additional differences in the risk of opioid-related death, we further classified admissions as psychiatric or nonpsychiatric; whether postdischarge risk periods followed discharge against medical advice or planned discharge; and whether postdischarge periods followed admissions of 1 day, 2 to 6 days, or 7+ days. We classified admissions as “psychiatric” if the patient was admitted to a specialist mental health provider or if the lead treatment specialty was recorded as “mental health.” We classified discharges as “against medical advice” if the doctor recorded the discharge method as “self-discharged or discharged by a relative or advocate” [15].

Some deaths occurred in hospital. If a patient was admitted due to drug poisoning (see Fig A in S1 Appendix for detail on how we classified these admissions), we moved the date of death to immediately prior to admission and censored the final admission. If a patient died on the day of discharge and hospital data showed that the patient died in the hospital, the death
was assigned to exposure status A or B (currently in hospital), while if the hospital data showed that the patient was discharged alive, exposure status C was assigned (discharged in the past 1 to 2 days). For 28 individuals, we found discordant data in which hospital discharge dates were recorded long after death dates. These discrepant dates are likely due to failed linkage rather than inaccuracies in hospital discharge or death dates, and we excluded these individuals from the study. A small number of individuals had admissions in the 3 days after death, for example, for organ donation, and these cases were retained.

### Statistical analysis

We described the characteristics of deaths included in the study and then used conditional logistic regression (stratified by individual) to estimate the association between hospital admission and opioid-related death. The reference category was time neither admitted to hospital nor recently discharged (category E). We repeated the analysis with stratification by sex. We published a protocol before doing analysis [16]. In our protocol, the primary analysis was a self-controlled case series design and have included results using this approach in Fig D and
Table B in S1 Appendix. We chose a case-crossover design instead because it allowed analysis of exposures with varying durations. Analysis was conducted using R version 4.0.3.

This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline [17] (see Table D in S1 Appendix).

Results

Description of cases

The study included 13,609 opioid-related deaths. A total of 9,765/13,609 decedents (71.8%) were male, 12,437/13,609 (91.4%) had “white” ethnicity, the median age at death was 42 (interquartile range [IQR] 35 to 49), and decedents predominantly lived in deprived neighbourhoods. Table 1 summarises the characteristics of cases.

Most opioid-related deaths (11,629/13,609, 85.5%) did not occur in the hospital or within 14 days of discharge. A total of 656/13,609 deaths (4.8%) occurred in hospital following admission due to drug poisoning. 236/13,609 deaths (1.7%) occurred during a hospital admission where the patient was admitted for a reason other than drug poisoning. The remaining 1,088/13,609 deaths (8.0%) occurred in the 14 days after discharge. Based on published data, we estimated that our study excluded 11.8% of deaths because the decedent was never admitted to the hospital (Fig 1). This suggests that in the population, 7.1% of opioid-related deaths occur in the 14 days after discharge.

Characteristics of hospital admissions in the 2 years prior to death

A total of 37,570 hospital admissions occurred in the 730 days prior to death, with a median of 1 (IQR 0 to 4) per individual. 3,742/37,570 (10.0%) of admissions ended in discharge against medical advice, and 3,418/37,570 (9.1%) were classified as psychiatric admissions. Table 2 summarises the characteristics of hospital admissions in the 2 years prior to death.

Results of case-crossover analysis

Days 1 to 14 of hospital admissions had a similar risk of opioid-related death as periods in the community (conditional odds ratio of 1.03; 95% CI 0.87 to 1.21; \( p = 0.95 \)). Days 15+ of hospital admission were associated with lower risk of opioid-related death (conditional odds ratio of 0.41; 95% CI 0.30 to 0.56; \( p < 0.001 \)).

The risk of opioid-related death increased substantially after discharge, with a conditional odds ratio of 4.39 (95% CI 3.75 to 5.14; \( p < 0.001 \)) in days 1 to 2 after discharge and 2.09 (95% CI 1.92 to 2.28; \( p < 0.001 \)) in days 3 to 14. The risk was higher for people discharged after a psychiatric admission and for people who left the hospital against medical advice. Longer admissions were associated with greater risk of opioid-related death after discharge, and we observed this gradient in days 1 to 2 after discharge and days 3 to 14. Results of the case-crossover analysis are shown in Fig 3. Sex-stratified results suggested similar associations for men and women. Sensitivity analysis with control days sampled from 365 to 28 days before death showed slightly smaller associations between hospital discharge and opioid-related death, and sensitivity analysis with control days sampled from 1,095 to 28 days before death showed slightly larger associations. Full results for stratified analyses and sensitivity analyses are provided in Figs D and E and Table C in S1 Appendix.

Discussion

In this nationwide study of opioid-related deaths in England over 10 years, we found that the risk of death is very high in the 2 weeks after hospital discharge, and this period accounts for 1
in 14 deaths. Patients who leave the hospital against medical advice and those leaving the hospital after a longer stay have higher risk. We also identified 236 cases where the data suggest that an opioid-related death occurred during a hospital admission. While each of these cases is a serious and potentially preventable incident, the overall results of our study suggest that the

---

| Variable                        | Level                                      | Number (%) |
|---------------------------------|--------------------------------------------|------------|
| Total                           |                                            | 13,609 (100.0) |
| Age at death                    | Median [IQR]                               | 42 [35–49] |
|                                 | Mean [SD]                                  | 41.9 [10.0] |
| Sex                             | Male                                       | 9,765 (71.8) |
|                                 | Female                                     | 3,844 (28.2) |
| Ethnicity*                      | White British, White Irish, or Other White | 12,437 (91.4) |
|                                 | Asian or Asian British                     | 193 (1.4)   |
|                                 | Other                                       | 145 (1.1)   |
|                                 | Black or Black British                     | 133 (1.0)   |
|                                 | Mixed                                       | 99 (0.7)    |
|                                 | Unknown                                     | 602 (4.4)   |
| Deprivation (IMD)               | 1: Most deprived                           | 6,067 (44.6) |
|                                 | 2                                           | 3,370 (24.8) |
|                                 | 3                                           | 1,940 (14.3) |
|                                 | 4                                           | 1,328 (9.8)  |
|                                 | 5: Least deprived                           | 790 (5.8)    |
|                                 | Missing                                     | 114 (0.8)   |
| Year of death                   | 2010–2011                                   | 2,127 (15.6) |
|                                 | 2012–2013                                   | 2,442 (17.9) |
|                                 | 2014–2015                                   | 3,094 (22.7) |
|                                 | 2016–2017                                   | 3,323 (24.4) |
|                                 | 2018–2019                                   | 2,623 (19.3) |
| Geographical region             | North West                                  | 2,550 (18.7) |
|                                 | South East                                  | 1,894 (13.9) |
|                                 | Yorkshire and The Humber                    | 1,636 (12.0) |
|                                 | South West                                  | 1,384 (10.2) |
|                                 | West Midlands                               | 1,356 (10.0) |
|                                 | London                                      | 1,236 (9.1)  |
|                                 | East of England                             | 1,184 (8.7)  |
|                                 | North East                                  | 1,112 (8.2)   |
|                                 | East Midlands                               | 796 (5.9)     |
|                                 | Missing                                     | 459 (3.4)    |
| Proximity in time to hospital admission | Died in hospital (admitted after opioid use) | 656 (4.8) |
|                                 | Died in hospital (admitted for other reasons)| 236 (1.7) |
|                                 | Died in the 14 days after discharge         | 1,088 (8.0)  |
|                                 | Not in hospital or within 2 weeks of discharge | 11,629 (85.5) |

* Ethnicity is derived from the hospital data. Where a participant had hospital admissions with different recorded ethnic categories, we used the most commonly recorded category or the most recent category where multiple categories had the same frequency.

IMD, Index of Multiple Deprivation, derived from the Lower Super Output Area of the patient’s home address; IQR, interquartile range.

https://doi.org/10.1371/journal.pmed.1003759.t001
The risk of opioid-related death during hospital admissions is similar or lower than during time spent in the community.

**Comparison with other studies**

We are aware of one other study that has investigated deaths due to drug poisoning in relation to hospital admissions [18,19]. This study used a cohort of people registered for drug treatment in Scotland and reported the rate of drug-related deaths according to time proximity to hospital admissions. The referent in this study was the mortality rate among people who were never admitted to the hospital, and the results may therefore reflect differences between people who were admitted to the hospital and those who were not. The associations are much greater than in our study; for example, the mortality rate in the 28 days after discharge is 15 times that of individuals who were never admitted. Even periods more than 1 year after discharge have 3 times the rate, suggesting that these differences are unlikely to relate to the hospital admission itself.

Research has shown that other life events are also associated with opioid-related deaths. In particular, studies in several countries have found a high risk of drug-related death immediately after the release from prison [20–23] and a protective effect of opioid agonist therapy during this period [24]. Another example is the first 2 weeks after cessation of community-based opioid agonist therapy [25]. These are times when opioid agonist therapy is interrupted, tolerance is changing, and people may get drugs from a different source or use drugs in different ways.

**Strengths and limitations**

By studying all opioid-related deaths in England, we were able to include people who have never been in drug treatment, a group that is often excluded from studies of this population. The design also meant that we were able to estimate the absolute number of opioid-related deaths that occurred during hospital admissions (236 over 10 years). It also provided power to observe the risk associated with different types and durations of hospital admission, which would be challenging even with an extremely large cohort study.

While the self-controlled methodology eliminates time-invariant confounders, the results may partially be explained by escalating drug use or deteriorating health over time. It is

---

**Table 2. Characteristics of hospital admissions in the 2 years prior to opioid-related deaths in England from January 1, 2010 to December 31, 2019.**

| Variable          | Level | Number (%)
|-------------------|-------|-------------
| Total             |       | 37,570 (100.0)
| Discharged AMA    | Yes   | 3,742 (10.0) 
|                   | No    | 33,828 (90.0) 
| Length of admission (days) |       |          
|                   | 1     | 15,026 (40.0) 
|                   | 2–6   | 14,615 (38.9) 
|                   | 7+    | 7,929 (21.1) 
|                   | Median [IQR] | 2 [1–5] 
|                   | Mean [SD] | 8.7 [38.2] 
| Psychiatric admission | No   | 34,152 (90.9) 
|                   | Yes   | 3,418 (9.1) 
| Drug poisoning    | No    | 32,625 (86.8) 
|                   | Yes   | 4,945 (13.2) 

AMA, discharge against medical advice; IQR, interquartile range.

https://doi.org/10.1371/journal.pmed.1003759.t002

risk of opioid-related death during hospital admissions is similar or lower than during time spent in the community.
possible, for example, that someone in poor health or at times of more intense drug use would be more likely to be admitted to the hospital and more susceptible to death after using opioids. We tried to limit this type of confounding by selecting control days no more than 2 years before death. The density of hospital admissions does increase before death, but this increase is gradual (Fig C in S1 Appendix).

Our data did not include detailed information about drug use or enrollment in drug treatment services. We therefore could not confirm that participants were using drugs on the control days. People who used illicit opioids during the past decade in England have mostly been using drugs for many years. For example, in a cross-sectional survey of people who injected drugs in England in 2019, the median duration of drug use was 16 years, and only 6% of participants had injected for less than 2 years [26].

Our use of a national hospital dataset meant that we were able to include all hospital admissions in England, but it also meant that we had limited detail about individual patients. One limitation relates to “discharge against medical advice.” This was a binary variable in our analysis, when in reality there are a range of scenarios where discharge is negotiated between patients and hospital staff. A second limitation relates to our classification of hospital admissions ending in opioid-related death. If an admission ended in opioid-related death and the
primary cause of admission was a common complication of opioid poisoning, such as cardiac arrest, then we assumed that the indication for admission was related to opioid poisoning. This is a sensitive approach, and, in some cases, the opioid poisoning may have happened while the patient was in the hospital. Therefore, it is possible that we have underestimated the association between hospital admissions (exposure periods A and B) and opioid-related death.

Although our definition of opioid-related death is widely used, its validity is not known. It can be difficult to determine the cause of death when someone dies suddenly and alone. It is possible that some participants in our study who died shortly after a hospital admission died for reasons related to the admission (such as an acute infection) rather than due to opioid poisoning. If the cause of death is unclear but the individual was known to use illicit drugs, a doctor may assume that the death was primarily due to drug use. This type of misclassification may partly explain the association between hospital discharge and opioid-related death.

**Interpretation**

We identified 3 reasons why discharge from the hospital may be associated with increased risk of opioid-related death. First, opioid tolerance could reduce during an admission. Animal models suggest that opioid tolerance has a half-life of 6 days [27], supporting reductions in tolerance after admissions of 2 to 6 days or 7+ days (the categories used in our analysis). We also saw increased risk after admissions of only 1 day, suggesting that other mechanisms are also important. Second, opioid agonist therapy may be interrupted or reduced either at admission or discharge (see Box 1). This may further contribute to reduced tolerance and increase the likelihood that patients will use riskier opioids such as injected heroin. Third, patients may have an acute illness that makes them more vulnerable to death after using opioids, particularly respiratory problems such as pneumonias and acute exacerbations of chronic obstructive pulmonary disease. These are common reasons for hospital admission in this population [28] and increase the risk associated with central nervous system depressants. Painful conditions may also be important because they are associated with increased use of illicit and prescribed opioids.

**Box 1. Interpretation by a client representative at a community drug and alcohol service**

I know from personal experience and that of my peers that hospitals can be hostile, particularly when you are admitted in an emergency. Planned stays give you time to get prepared and make sure you have enough drugs to carry you through. When the stay is unplanned, you are reliant on the doctors giving you methadone or buprenorphine. They are not experts in this field and can be suspicious or at best conservative with their doses. Although some staff do their best to help, it is often made clear they suspect you are “drug seeking.” You have to beg to get the help you need. Many of my peers have left the hospital early in withdrawal and pain. They might be buying drugs from someone they do not know, perhaps unwell and with reduced tolerance, then using in an alley or public toilet. It is not surprising that so many people die due to drug overdoses in the days after leaving the hospital. Part of the solution is better communication between the local drug services and the hospital. This could help patients get the medication they need to stay in the hospital and help people arrange transport, accommodation, and timely opioid substitution when they leave.
We observed a high risk soon after hospital discharge and estimate that 1 in 14 opioid-related deaths in the population occur during these 2 weeks. The safety of discharge may be improved with better linkage to community drug treatment services, and there is a need for research into interventions that can improve continuity of opioid agonist therapy between community and hospital settings. It is thought that half of people who die after using illicit opioids in England have never been in contact with drug treatment services [29]. Initiation of opioid agonist therapy in the hospital is therefore also important. A randomised trial showed that patients that started on buprenorphine in hospital and referred to a community drug service are more likely to continue with treatment and less likely to use illicit opioids, compared with those assigned to opioid detoxification [30]. Hospitals can also provide advice on reducing overdose risk, such as using small test doses and not using drugs alone, and tools to help reduce risk, such as basic life support training and take-home naloxone [31].

We found variation in the risk of opioid-related death in our detailed exposure periods. In particular, the period after discharge against medical advice was associated with opioid-related death. Discharge against medical advice may happen when a patient is experiencing pain or withdrawal and leaves the hospital to use illicit opioids. The finding that the risk of opioid-related death reduces after day 14 of a hospital admission should be treated with caution, because the subset of admissions that are longer than 14 days may be unusual. For example, these patients may have less severe drug dependence or better controlled pain and be less at risk of opioid-related death for these reasons.

In many countries, the average age of people who use illicit opioids is increasing, and the frequency of long-term conditions is also increasing [32]. People who use illicit opioids do not always seek timely healthcare, in part due to fear of stigma, opioid withdrawal in the hospital, and poor pain management [33]. Hospitals that enable patients to disclose illicit drug use without fear of discrimination will be a central element of accessible and high-quality hospital care for this population.

Conclusions
Discharge from the hospital is associated with an acute increase in the risk of opioid-related death, and 1 in 14 opioid-related deaths in England happens in the 2 weeks after the hospital discharge. This supports interventions that prevent early discharge and improve linkage with community drug treatment and harm reduction services.

Supporting information
S1 Appendix. Table A: Distribution of ICD-10 diagnoses in opioid-related deaths in England between January 1, 2010 and December 31, 2019. Table B: Results of alternative self-controlled methodologies. Values are conditional odds ratios of opioid-related deaths (95% CIs). Table C: Results of case-crossover analysis stratified by sex and calendar year of death. Values are conditional odds ratio of opioid-related death (95% CIs). Table D: STROBE Checklist. Fig A: Flowchart showing how the exposure status on the day of death was determined. Fig B: Distribution of age at death for 13,609 people who died due to fatal opioid overdose in England between January 1, 2010 and December 31, 2019. Deaths at ages under 18 or over 65 were excluded from the study. Fig C: Number of hospital admissions in the 730 days prior to death among 13,609 people who died due to opioid overdose in England between January 1, 2010 and December 31, 2019, by 10-day period. Fig D: Results of alternative self-controlled methodologies. The chart shows conditional odds ratios with 95% CIs. Fig E: Results of case-crossover analysis stratified by sex and calendar year of death. Values are conditional odds ratio of opioid-related death (95% CIs). ICD-10, International Classification of Diseases-10th Revision;
STROBE, Strengthening the Reporting of Observational Studies in Epidemiology. (PDF)

Author Contributions

Conceptualization: Dan Lewer, Brian Eastwood, Martin White, Martin McCusker, Caroline Copeland, Michael Farrell, Irene Petersen.

Data curation: Dan Lewer.

Formal analysis: Dan Lewer.

Funding acquisition: Dan Lewer.

Investigation: Dan Lewer, Brian Eastwood, Martin White, Thomas D. Brothers, Martin McCusker, Caroline Copeland, Michael Farrell, Irene Petersen.

Methodology: Dan Lewer, Brian Eastwood, Martin White, Thomas D. Brothers, Irene Petersen.

Software: Dan Lewer.

Supervision: Brian Eastwood, Martin White, Martin McCusker, Irene Petersen.

Visualization: Dan Lewer.

Writing – original draft: Dan Lewer.

Writing – review & editing: Dan Lewer, Brian Eastwood, Martin White, Thomas D. Brothers, Martin McCusker, Caroline Copeland, Michael Farrell, Irene Petersen.

References

1. Strike C, Robinson S, Guta A, Tan DH, O’Leary B, Cooper C, et al. Illicit drug use while admitted to hospital: Patient and health care provider perspectives. PLoS ONE. 2020; 15:e0229713. https://doi.org/10.1371/journal.pone.0229713 PMID: 32134973

2. Neale J, Tompkins C, Sheard L. Barriers to accessing generic health and social care services: a qualitative study of injecting drug users: Drug injectors and barriers to service use. Health Soc Care Community. 2007; 16:147–54. https://doi.org/10.1111/j.1365-2524.2007.00739.x PMID: 18290980

3. McNeil R, Small W, Wood E, Kerr T. Hospitals as a ‘risk environment’: An ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014; 105:59–66. https://doi.org/10.1016/j.socscimed.2014.01.010 PMID: 24508718

4. Chan Carusone S, Guta A, Robinson S, Tan DH, Cooper C, O’Leary B, et al. “Maybe if I stop the drugs, then maybe they’d care?”—hospital care experiences of people who use drugs. Harm Reduct J. 2019;16. https://doi.org/10.1186/s12954-019-0285-7 PMID: 30760261

5. Fanucchi LC, Lofwall MR, Nuzzo PA, Walsh SL. In-hospital illicit drug use, substance use disorders, and acceptance of residential treatment in a prospective pilot needs assessment of hospitalized adults with severe infections from injecting drugs. J Subst Abuse Treat. 2018; 92:64–9. https://doi.org/10.1016/j.jsat.2018.06.011 PMID: 30032946

6. Grewal HK, Ti L, Hayashi K, Dobrer S, Wood E, Kerr T. Illicit drug use in acute care settings. Drug Alcohol Rev. 2015; 34:499–502. https://doi.org/10.1111/dar.12270 PMID: 25944526

7. Reporter Sun. Dead patient lay undiscovered for THREE NIGHTS in an NHS hospital toilet ‘after drug overdose.’ The Sun. 2017 [cited 2021 Feb 8]. Available from: https://web.archive.org/save/https://www.thesun.co.uk/news/3998345/dead-patient-lay-undiscovered-for-three-nights-in-an-nhs-hospital-toilet-after-drug-overdose/

8. O’Brien Z. Patient who lay dead in a hospital toilet for two days wasn’t even reported missing until over FOUR HOURS after he left his ward for a cigarette. The Daily Mail. 2018 Apr 25 [cited 2020 Jul 20]. Available from: https://web.archive.org/web/20210208091452https://www.dailymail.co.uk/news/article-5656608/Patient-lay-dead-hospital-toilet-two-days-leaving-ward-cigarette-inquest-hears.html
9. Maclure M. The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. Am J Epidemiol. 1991; 133:144–53. https://doi.org/10.1093/oxfordjournals.aje.a115853 PMID: 1985444

10. Office for National Statistics. Deaths related to drug poisoning in England and Wales QMI. 2018. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/deaths/causersofdeath/englandandwales/qmi

11. Digital NHS. A Guide to Linked Mortality Data from Hospital Episode Statistics and the Office for National Statistics. 2015. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/datasets/hospital-episode-statistics-data-dictionary

12. Office for National Statistics. Deaths related to drug poisoning by selected substances. 2020. Available from: https://digital.nhs.uk/peoplepopulationandcommunity/deaths/causersofdeath/englandandwales/qmi

13. Digital NHS. Hospital Admitted Patient Care Activity 2018–19. NHS Digital; 2019. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2018-19

14. Johnson H, Brock A, Griffiths CE, Rooney C. Mortality from suicide and drug-related poisoning by day of the week in England and Wales, 1993–2002. Health Stat Q. 2005; 27:13–6.

15. Digital NHS. HES Data Dictionary: Admitted Patient Care. 2020. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/datasets/hospital-episode-statistics-data-dictionary

16. Lewer D, Copeland C, Eastwood B, Farrell M, Petersen I, White M. Fatal opioid overdoses in healthcare settings in England: a case series analysis (PROTOCOL). UCL Research Department of Epidemiology & Public Health; 2020. https://doi.org/10.14324/000.rp.10116745

17. von E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med. 2007; 4:e296. https://doi.org/10.1371/journal.pmed.0040296 PMID: 17941714

18. White SR, Bird SM, Merrall ELC, Hutchinson SJ. Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors. PLoS ONE. 2015; 10: e0141073. https://doi.org/10.1371/journal.pone.0141073 PMID: 26539701

19. Merrall ELC, Bird SM, Hutchinson SJ. A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996–2006: Drug-related death after hospital discharge. Addiction. 2013; 108:377–84. https://doi.org/10.1111/j.1360-0443.2012.04066.x PMID: 22925008

20. Zlodre J, Fazel S. All-Cause and External Mortality in Released Prisoners: Systematic Review and Meta-Analysis. Am J Public Health. 2012; 102:e67–75. https://doi.org/10.2105/AJPH.2012.300764 PMID: 23078476

21. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ. 1998; 316:426–8. https://doi.org/10.1136/bmj.316.7129.426 PMID: 9492665

22. Binswanger IA, Heagerty PJ, Koepsell TD. Release from Prison—a High Risk of Death for Former Inmates. N Engl J Med. 2007; 356:157–65. https://doi.org/10.1056/NEJMsa064115 PMID: 17215533

23. Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison: Drug-related deaths after release from prison. Addiction. 2010; 105:1545–54. https://doi.org/10.1111/j.1360-0443.2010.02990.x PMID: 20579009

24. Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study: Impact of OST on mortality post-release from prison. Addiction. 2014; 109:1306–17. https://doi.org/10.1111/adb.12536 PMID: 24612249

25. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357. https://doi.org/10.1136/bmj.j550 PMID: 28446428

26. Public Health England. Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among PWID: 2020 report. Public Health England; 2020. Available from: https://www.gov.uk/government/publications/people-who-inject-drugs-hiv-and-viral-hepatitis-monitoring

27. Dumas EO, Pollack GM. Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective. AAPS J. 2008; 10:537. https://doi.org/10.1208/s12248-008-9056-1 PMID: 18989788

28. Lewer D, Tweed EJ, Aldridge RW, Morley KI. Causes of hospital admission and mortality among 6683 people who use heroin and crack cocaine, comparing relative and absolute risks: a population-based
cohort study. Drug Alcohol Depend. 2019. https://doi.org/10.1016/j.drugalcdep.2019.06.027 PMID: 31581023

29. White M, Hamilton B. Trends in drug misuse deaths in England, 1999 to 2014. Public Health England; 2016. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/669620/Trends_in_drug_misuse_deaths_in_England_from_1999_to_2014.pdf

30. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine Treatment for Hospitalized, Opioid-Dependent Patients: A Randomized Clinical Trial. JAMA Intern Med. 2014; 174:1369. https://doi.org/10.1001/jamainternmed.2014.2556 PMID: 25090173

31. Brothers TD, Fraser J, Webster D. Caring for people who inject drugs when they are admitted to hospital. CMAJ. 2021;193. https://doi.org/10.1503/cmaj.202124 PMID: 33753366

32. Advisory Council on the Misuse of Drugs. ACMD report: ageing cohort of drug users. UK Government; 2019. Available from: https://www.gov.uk/government/publications/acmd-report-ageing-cohort-of-drug-users

33. Harris M. Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care. Soc Sci Med. 2020; 260:113183. https://doi.org/10.1016/j.soscimed.2020.113183 PMID: 32682207
Supplementary Information

S1. Summary of ICD-10 diagnoses recorded in opioid-related deaths .............................................. 2
S2. Determination of exposure status for deaths .................................................................................. 3
S3. Histogram of age of participants at death .................................................................................... 4
S4. Density of hospital admission prior to death ................................................................................. 5
S5. Results of planned analysis ........................................................................................................... 6
S6. Results stratified by sex and calendar year .................................................................................. 8
S7. STROBE checklist ........................................................................................................................ 10
S8. References for supplementary information .................................................................................. 13
### S1. Summary of ICD-10 diagnoses recorded in opioid-related deaths

Table A: distribution of ICD-10 diagnoses in opioid-related deaths in England between 1 January 2010 and 31 December 2019

| ICD-10 code of underlying cause of death | Number of deaths (% of column) | Opioids recorded as contributing causes of death. All deaths apart from those with an underlying cause of F11 have at least one of these codes* (% of row) |
|-----------------------------------------|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Total                                   | 13,609 (100.0)                 | T40.1 Heroin | T40.2 Other opioids | T40.3 Methadone | T40.4 Other synthetic narcotics | T40.6 Unspecified narcotics |
| X42: accidental poisoning by narcotics and psychodysleptics | 10,190 (74.9)                  | 3,549 (34.6) | 3,679 (38.1) | 2,521 (24.7) | 1,107 (10.9) | 882 (6.7) |
| X62: intentional self-poisoning by narcotics and psychodysleptics | 1,006 (7.4)                    | 75 (7.5)     | 619 (61.5)      | 63 (6.3) | 291 (28.9) | 56 (5.6) |
| X44: accidental poisoning by other or unspecified drugs | 860 (6.3)                      | 163 (19.0)   | 371 (43.1)      | 345 (40.1) | 140 (16.3) | 53 (6.2) |
| Y12: poisoning by narcotics and psychodysleptics, undetermined intent | 831 (6.1)                      | 121 (14.6)   | 439 (52.8)      | 116 (14.0) | 179 (21.5) | 61 (7.3) |
| F11: mental and behavioural disorders due to use of opioids | 288 (2.1)                      | 24 (8.3)     | 17 (5.9)        | 24 (8.3) | 1-4** | 10-14** |
| X64: intentional self-poisoning by other or unspecified drugs | 194 (1.4)                      | 1-4**        | 130 (67.0)      | 15-19** | 57 (29.4) | 5-9** |
| Y14: poisoning by other or unspecified drugs, undetermined intent | 140 (1.0)                      | 5-9**        | 97 (69.3)       | 25 (17.9) | 38 (27.1) | 1-4** |
| X41: accidental poisoning by antiepileptic, sedative-hypnotic, antiparkinsonism and psychotrophic drugs | 53 (0.4)                        | 5-9**        | 18 (34.0)       | 20 (37.7) | 12 (22.6) | 5-9** |
| Other underlying cause of death | 47 (0.3)                       | 5-9**        | 29 (61.7)       | 5-9** | 5-9** | 1-4** |

* The case definition also included deaths where T40.0 (poisoning by opium) was recorded, but no deaths with this code were found.

** Censored to prevent disclosure of small cell counts.
S2. Determination of exposure status for deaths

Figure A: Flowchart showing how the exposure status on the day of death was determined

Notes:

Among admissions ending in opioid-related death, admissions due to opioid use identified as those with:

- A drug-related primary diagnosis: ICD-10 X40-44, X60-64, X85, or Y10-Y14 recorded as the primary reason for admission.
- An opioid in any diagnostic position: T40.0-T40.4 or T40.6.
- A primary diagnosis of a known complication of opioid overdose. Consistent with a previous study,[1] we defined the complications as: encephalopathy (G92, G93.1, G93.2); ARDS (J80); respiratory failure (J96.0, J96.9); pulmonary haemorrhage (R04.8); aspiration pneumonia (J69.0); cardiac arrest (I46); ventricular arrhythmia (I47.0, I47.2, I49.0); heart failure (I50); rhabdomyolysis (M62.8, T79.6); paraplegia or tetraplegia (G82); acute renal failure (N17); and intentional self-harm (X60-X84).
S3. Histogram of age of participants at death

Figure B: distribution of age at death for 13,609 people who died due to fatal opioid overdose in England between 1 Jan 2010 and 31 December 2019. Deaths at ages under 18 or over 65 were excluded from the study.
S4. Density of hospital admission prior to death

The number of admissions in the cohort increased during the 730 days prior to death (see figure). This may be related to worsening health or escalating drug use prior to death, secular increases in the rate of hospital admission (in the general population, rates of age-specific hospital admission are increasing [2]), or ageing in the cohort. These factors are likely to explain some of the observed association between hospital admission and death, in addition to the acute effects of the hospital admission. The figure shows that this increase is gradual, which may suggest a limited contribution of these factors to the observed associations.

Figure C: number of hospital admissions in the 730 days prior to death among 13,609 people who died due to opioid overdose in England between 1 Jan 2010 and 31 December 2019, by 10-day period.
S5. Results of planned analysis

In our protocol [3] we planned to use a self-controlled case series (SCCS) method with observation between 1 January 2010 and 31 December 2019. An assumption of the standard SCCS method is that the observation of exposures (i.e. hospital admissions) is independent of the event.[4] In our study, the event is death and therefore observation of exposures ends at the event. To address this, we planned to use a method for event-dependent exposures designed by Farrington et al.[5] with time-varying age groups of 18-24, 25-34 ... 60-64. This method is only suitable for exposures of fixed duration and we were not able to use it for exposure periods A and B (the periods during hospital admission), which vary in duration. This is why we chose to use a case-crossover method in our main analysis. We did fit the model for exposure periods C and D, which are days 1-2 days 3-14 days after discharge and have fixed durations. We did not have sufficient computing resources to fit this model for the whole dataset and therefore used 10 random samples of 500 cases, with a pooled value estimated by fixed-effects meta-analysis, using the R function meta::metagen.[6] Note that this analysis assumes that exposure periods A and B (the hospital admission) have the baseline risk, which is unlikely to affect this analysis substantially because a relatively small proportion of follow-up time was spent in hospital. In addition, we fit models with follow-up ended at death; and with follow-up ended on 31 December 2019 with the time after death treated as exposure-free. Both of these methods were anticipated to be biased, with the model with follow-up ending at 31 December 2019 most strongly overestimating the relative risk associated with the exposure periods.

As a sensitivity analysis, we also repeated the case-crossover analysis with control periods sampled from the periods 365-28 days before death and 1095-28 days before death.

The results of these analyses are summarised in the figure and table below. As expected, the SCCS model with follow-up ending on 31 December 2019 showed the largest associations between hospital admission and the fatal opioid overdose. The model for event-dependent exposures produced very similar results to our main analysis. Case-crossover analyses with control windows in the more distant past produced larger associations. Very distant control windows are less likely to represent an ‘exchangeable’ exposure density (i.e. a probability of hospital admission that would be the same in the absence of the event).
Figure D: Results of alternative self-controlled methodologies. The chart shows conditional odds ratios with 95% confidence intervals.

Table B: Results of alternative self-controlled methodologies. Values are conditional odds ratios of opioid-related deaths (95% confidence intervals)

| Modelling approach                                      | A: Days 1-14 of admission | B: Days 15+ of admission | C: Days 1-2 after discharge | D: Days 3-14 after discharge |
|----------------------------------------------------------|----------------------------|--------------------------|-----------------------------|------------------------------|
| Control days sampled from 730-28 days before death (main analysis) | 1.03 (0.87-1.21)          | 0.41 (0.30-0.56)         | 4.39 (3.75-5.14)            | 2.09 (1.92-2.28)             |
| Control days sampled from 365-28 days before death      | 0.88 (0.75-1.04)          | 0.34 (0.25-0.47)         | 3.42 (2.94-3.97)            | 1.90 (1.75-2.07)             |
| Control days sampled from 1095-28 days before death     | 1.11 (0.94-1.31)          | 0.48 (0.35-0.66)         | 4.52 (3.86-5.30)            | 2.35 (2.15-2.56)             |
| Standard self-controlled case series; end follow-up at death | 1.70 (1.46-1.97)          | 0.75 (0.56-0.99)         | 6.17 (5.49-6.93)            | 3.28 (3.05-3.53)             |
| Standard self-controlled case series; end follow-up at 31 December 2019 | 2.66 (2.29-3.09)          | 1.23 (0.93-1.62)         | 9.53 (8.48-10.72)           | 5.06 (4.71-5.43)             |
| Farrington model for event-dependent exposures, pooled value from 10 samples of 500 cases | -                          | -                        | 4.80 (3.96-5.81)            | 2.28 (2.03-2.58)             |
S6. Results stratified by sex and calendar year

Figure E: results of case-crossover analysis stratified by sex and calendar year of death. Values are conditional odds ratio of opioid-related death (95% confidence intervals)
Table C: results of case-crossover analysis stratified by sex and calendar year of death. Values are conditional odds ratio of opioid-related death (95% confidence intervals)

| Stratification | Level | A: Days 1-14 of admission | B: Days 15+ of admission | C: Days 1-2 after discharge | D: Days 3-14 after discharge |
|----------------|-------|---------------------------|-------------------------|-----------------------------|-------------------------------|
| Sex            | Male  | 1.01 (0.82-1.23)          | 0.37 (0.25-0.55)        | 4.47 (3.70-5.40)            | 2.33 (2.11-2.58)              |
|                | Female| 1.06 (0.81-1.39)          | 0.52 (0.30-0.87)        | 4.20 (3.15-5.60)            | 1.62 (1.38-1.90)              |
| Calendar year  | 2010  | 0.91 (0.50-1.67)          | 0.41 (0.13-1.26)        | 2.87 (1.63-5.06)            | 2.08 (1.54-2.82)              |
|                | 2011  | 0.92 (0.51-1.65)          | 0.65 (0.28-1.49)        | 3.91 (2.26-6.76)            | 3.08 (2.34-4.06)              |
|                | 2012  | 1.20 (0.69-2.09)          | 0.21 (0.05-0.92)        | 4.83 (2.87-8.13)            | 2.40 (1.80-3.22)              |
|                | 2013  | 0.92 (0.55-1.55)          | 0.59 (0.23-1.52)        | 3.94 (2.22-6.98)            | 1.70 (1.28-2.25)              |
|                | 2014  | 0.65 (0.33-1.25)          | 0.37 (0.13-1.06)        | 5.75 (3.47-9.54)            | 1.82 (1.39-2.39)              |
|                | 2015  | 0.99 (0.63-1.58)          | 0.43 (0.19-0.96)        | 5.72 (3.64-8.99)            | 2.53 (2.02-3.18)              |
|                | 2016  | 1.43 (0.94-2.18)          | 0.37 (0.13-1.06)        | 4.64 (3.11-6.94)            | 2.04 (1.61-2.59)              |
|                | 2017  | 1.40 (0.91-2.14)          | 0.55 (0.23-1.31)        | 2.81 (1.72-4.61)            | 2.00 (1.54-2.58)              |
|                | 2018  | 0.68 (0.35-1.30)          | 0.27 (0.09-0.81)        | 4.37 (2.50-7.62)            | 2.04 (1.50-2.76)              |
|                | 2019  | 0.98 (0.59-1.64)          | 0.21 (0.05-0.90)        | 5.60 (3.37-9.29)            | 1.48 (1.10-1.99)              |
## S7. STROBE checklist

Table D: STROBE checklist

| Item No | Recommendation | Page No |
|---------|----------------|---------|
| **Title and abstract** | | |
| 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | Title, Abstract (“case-crossover”) |
| | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract |
| **Introduction** | | |
| 2 | Explain the scientific background and rationale for the investigation being reported | Introduction |
| **Objectives** | | |
| 3 | State specific objectives, including any prespecified hypotheses | Introduction ¶3 |
| **Methods** | | |
| 4 | Present key elements of study design early in the paper | Methods ¶1 |
| 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Methods/study participants |
| 6 | (a) **Cohort study**—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up **Case-control study**—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls **Cross-sectional study**—Give the eligibility criteria, and the sources and methods of selection of participants | Methods/study participants; Methods/control days |
| | (b) **Cohort study**—For matched studies, give matching criteria and number of exposed and unexposed **Case-control study**—For matched studies, give matching criteria and the number of controls per case | Methods/control days |
| 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Methods/control days; Methods/exposure status |
| 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods/exposure status; Supplementary Information/determination of exposure status for deaths |
| 9 | Describe any efforts to address potential sources of bias | Methods ¶1; Methods/control days |
| 10 | Explain how the study size was arrived at | Fig 1 |
| 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Methods/exposure status |
| Item No | Recommendation | Page No |
|--------|----------------|---------|
| **Statistical methods** | | |
| 12 | (a) Describe all statistical methods, including those used to control for confounding | Methods/statistical analysis |
|  | (b) Describe any methods used to examine subgroups and interactions | Methods/statistical analysis; Supplementary Information/results stratified by sex and calendar year |
|  | (c) Explain how missing data were addressed | NA |
|  | (d) *Cohort study*—If applicable, explain how loss to follow-up was addressed.  
*Case-control study*—If applicable, describe analytical methods taking account of sampling strategy | Methods ¶1 (matching is within individuals) |
|  | (e) Describe any sensitivity analyses | Methods/statistical analysis; Supplementary Information/results of planned analysis |

| **Results** | | |
| **Participants** 13* | | |
| (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Methods/study participants; Results/description of cases; Fig 1 |
| (b) Give reasons for non-participation at each stage | Methods/study participants; Fig 1 |
| (c) Consider use of a flow diagram | Fig 1 |
| **Descriptive data** 14* | | |
| (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Results/description of cases; Table 1 |
| (b) Indicate number of participants with missing data for each variable of interest | Table 1 (data were only missing for region, deprivation, and ethnicity, which were only used to describe the sample rather than in analysis) |
| (c) *Cohort study*—Summarise follow-up time (eg, average and total amount) | NA (case-crossover study) |
| **Outcome data** 15* | | |
| *Cohort study*—Report numbers of outcome events or summary measures over time | NA (case-crossover study) |
| *Case-control study*—Report numbers in each exposure category, or summary measures of exposure | NA (case-crossover study) |
| *Cross-sectional study*—Report numbers of outcome events or summary measures | NA (case-crossover study) |
| **Main results** 16 | | |
| (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Results/results of case-crossover analysis; Fig 3 |
| (b) Report category boundaries when continuous variables were categorized | Methods/exposure status (exposure boundaries, e.g. 1-2 days after hospital discharge) |
| Item No | Recommendation | Page No |
|---------|----------------|---------|
| (c) | If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA |
| Other analyses | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Results/results of case-crossover analysis ¶2; Supplementary Information/results of planned analysis; Supplementary Information/results stratified by sex and calendar year |
| **Discussion** | | |
| Key results | Summarise key results with reference to study objectives | Discussion ¶1 |
| Limitations | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion/strengths and limitations ¶2-5 |
| Interpretation | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion ¶1; Discussion/interpretation |
| Generalisability | Discuss the generalisability (external validity) of the study results | NA |
| **Other information** | | |
| Funding | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Additional information/funding |
S8. References for supplementary information

1 Morrow RL, Bassett K, Maclure M, et al. Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study. BMJ Open 2019;9:e025567. doi:10.1136/bmjopen-2018-025567

2 NHS Digital. Hospital Admitted Patient Care Activity 2018-19. 2019. https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2018-19 (accessed 5 Feb 2021).

3 Lewer D, Copeland C, Eastwood B, et al. Fatal opioid overdoses in healthcare settings in England: a case series analysis (PROTOCOL). 2020. https://doi.org/10.14324/000.rp.10116745

4 Whitaker HJ, Ghebremichael-Weldeselassie Y. Self-Controlled Case Series Methodology. Annu Rev Stat Its Appl 2019;6:241–61. doi:10.1146/annurev-statistics-030718-105108

5 Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics 2008;10:3–16. doi:10.1093/biostatistics/kxn013

6 Schwarzer G. meta: An R Package for Meta-Analysis. R News 2007;7:40–5.